SELECTION OF DRUG RESISTANCE IN MALARIA PARASITES

疟疾寄生虫的耐药性选择

• 批准号: 6132691
• 负责人: Carol Hopkins Sibley
• 金额: $ 3.85万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2003-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6132691
• 关键词: Africa; Plasmodium falciparum; alleles; antimalarial agents; clinical research; communicable disease transmission; cooperative study; drug resistance; epidemiology; folate antagonist; gene frequency; gene mutation; genotype; human genetic material tag; human subject; human therapy evaluation; longitudinal human study; malaria; microorganism disease chemotherapy; microorganism genetics; outcomes research; pharmacogenetics; polymerase chain reaction; statistics /biometry

This grant will study the acquisition of drug resistance by malarial parasites. Resistance to antimalarial drugs is correlated with genetic changes in malarial enzymes called DHPS and DHFR (dihydropteroate synthase and dihydrofolate reductase). Malarial parasites resistant to these drugs carry alleles of DHPS and DHFR that contain point mutations reducing binding of drug to enzyme. Therefore, the goal of the project is to compare the rates of change in parasite alleles known to be associated with drug resistance, to identify selective forces that influence the rate of selection of drug resistance in Kenya. Subsequently, this information will influence public health decisions in treatment protocols for malaria in East Africa.

这笔赠款将研究疟疾寄生虫获得耐药性的情况。 抗疟药物耐药性与疟疾基因变化相关 称为 DHPS 和 DHFR（二氢蝶酸合成酶和二氢叶酸 还原酶）。对这些药物具有抗药性的疟疾寄生虫携带 DHPS 等位基因 DHFR 含有减少药物与酶结合的点突变。 因此，该项目的目标是比较变化率 已知与耐药性相关的寄生虫等位基因，以确定 影响耐药性选择率的选择力 肯尼亚。随后，这些信息将影响公共卫生决策 东非疟疾的治疗方案。